Menarini Diagnostics (UK) Cellular Pathology services

Latest News

Innovation in Transplantation: The Digital Era

6th-8th June the Fondazione Internazionale Menarini hosted the congress "Innovation in Transplantation: The Digital Era"  in Verona. This two day congress with high level speakers from Europe attracted over 170 key opinion leaders from the transplantation and digital pathology society. We had 10 attendees from UK attending the event. One of the highlights of the congress was Dr Desley Neil's presentation about the kidney quality assessment and its limits.

Read more: Innovation in Transplantation: The Digital Era

Register now! Webinar about formalin free handling of surgical specimens from operating theatres to histopathology laboratories

Menarini Diagnostics are pleased to invite you to attend a webinar about formalin free surgical specimen handling from operating theatres to histopathology laboratories on the 10th May. 

The webinar will provide a comprehensive description on the validation procedure, which allows samples to be transported from operating theatres to pathology laboratories in safer and more economical manner. 

Read more: Register now! Webinar about formalin free handling of surgical specimens from operating theatres...

On-Board Embedding Now Available on Your Tissue Processor Patient Centred Processing

Have you heard about Synergy? It’s a revolutionary patented method to embed tissues on-board your tissue processor, as part of the processing protocols. Menarini’s Pathos Delta and Logos Hybrid Tissue Processors can both be used with the dedicated Synergy rack and consumables to achieve on-board embedding. A variety of tissue types and dimensions can be processed and embedded with this method.

Read more: On-Board Embedding Now Available on Your Tissue Processor Patient Centred Processing

Association of Anatomical Pathology Technology 30th September 2017 Cardiff

Menarini Diagnostics recently attended the Association of Anatomical Pathology Technology conference in Cardiff. The annual AAPT conference is an opportunity for delegates to update their knowledge of scientific, technological, legal and social issues relating to the healthcare science profession of anatomical pathology technology. The AAPT conference was attended mostly by mortuary technicians and presentations covered for instance diseases in the mortuary, inspection preparation and organ donation. On the Total Tissue Diagnostics exhibition stand there was the opportunity to see the Gold standard for digital imaging, the MacroVIEW DM that gathered a large of amount of interest. We would like to thank everyone that joined us at the meeting and we look forward to seeing you again.

“All cancer patients should have their DNA tested to save lives”, Chief Medical Officer says

The report from England's chief medical officer Professor Dame Sally Davies details the ambition of NHS England to routinely provide genetic testing for cancer patients within the next five years. Professor Sally Davies wants whole genome sequencing to become as standard as blood tests and biopsies. In about two-thirds of cases, this type of information can improve the diagnosis and allows doctors to tailor treatment to the individual, ensuring patients receive the most effective drugs. At the moment more than 31,000 NHS patients have had their entire genetic code sequenced since 2013. At present there are 25 regional laboratories performing this type of genetic testing.

Read more: “All cancer patients should have their DNA tested to save lives”, Chief Medical Officer says

Not Just Conventional Tissue Processing!

Patient Centred Processing is a new approach from Menarini to ensure that all patient samples are handled safely and quickly, to increase laboratory throughput and provide an accurate and fast turnaround time of results to patients.

There is a ‘national ambition in England to achieve earlier diagnosis’ as indicated in a report of the Independent Cancer Taskforce. The recommendation is that 95% of patients referred for testing by a GP should receive their results within 4 weeks by 2020.

Read more: Not Just Conventional Tissue Processing!

IMPORTANT INFORMATION NOTICE

On January 1st 2016, formaldehyde was reclassified as a Category 1B carcinogen and Category 2 mutagen under the CLP (Classification, Labelling and Packaging) Regulations EC 1272/2008.

Category 1B substances are presumed to have carcinogenic potential for humans. Therefore under COSHH there is a duty on employers to reduce exposure to such substances to as low a level as is reasonably practicable.

Read more: IMPORTANT INFORMATION NOTICE